With results in lung and breast cancer, AstraZeneca won cancer’s big meeting — again

But can the company ride its winning streak to $80 billion? 

June 7, 2024 Check out STAT+

Sponsored By

Marie Miller for STAT STAT+ | ASCO24: AstraZeneca won cancer's big meeting — again. Will that help it fulfill its $80 billion ambition? It's a harsh reality in the pharmaceutical business that winning streaks tend to end — and cruelly. But AstraZeneca believes it has reason for optimism. By Matthew Herper STAT+ | Illumina board agrees to spin off Grail, as divestment plans proceed It's the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. By Jason Mast STAT+ | Delfi Diagnostics announces key data, study design for its liquid biopsy test Delfi is focusing on a single disease — lung cancer — where the utility of screening with existing technology is not in dispute. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser